Acalabrutinib, a second-generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off-target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). This evidence concerns the gene IBTK and B-cell chronic lymphocytic leukemia.